Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Idalia Liboy"'
Autor:
Noridza Rivera, Caroline Rivera, Idalia Liboy, Wandaly I. Pardo, Fernando Cabanillas, Pedro Gil Solivan, Mirelis Acosta
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:776-783
Purpose To evaluate the impact of lenalidomide in patients with aggressive lymphoma who experienced less than complete response (CR) or as maintenance therapy after CR after gemcitabine, rituximab, and oxaliplatin salvage chemotherapy (GROC-Rev regim
Autor:
Juan Arraut-Gonzalez, José G. Conde, Idalia Liboy, Jorge Bertrán-Pasarell, Yaimara Hernandez-Silva, Javier Morales, Ricardo Fernández, James Bryan-Díaz, Fernando Cabanillas
Publikováno v:
medRxiv
IntroductionCovid-19 is a triphasic disorder first typified by a viral phase that lasts from the first onset of symptoms until seven days later. This is followed by a second and third phase, initially characterized by the appearance of lung infiltrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314251335beafa2d576ca754d26ebf91
https://europepmc.org/articles/PMC7987043/
https://europepmc.org/articles/PMC7987043/
Autor:
Jorge Bertrán-Pasarell, Fernández R, Idalia Liboy, José G. Conde, Fernando Cabanillas, Hernandez-Silva Y, Morales J
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
BackgroundCovid-19 is a triphasic disorder characterized by a viral phase lasting 7-10 days from onset of symptoms. In approximately 20% it is followed by a second stage heralded by elevation of pro-inflammatory markers such as ferritin, IL-6, CRP, L
Autor:
Wandaly I. Pardo, Pedro Gil Solivan, Idalia Liboy, Mirelis Acosta, Fernando Cabanillas, Alexis Cruz, Noridza Rivera
Publikováno v:
Journal of Clinical Oncology. 35:7556-7556
7556 Background: Currently there is no optimal salvage regimen for relapsed/refractory NHL (R/R NHL). Prognosis of pts who fail to achieve CR to salvage therapy is dismal. We sought to improve the CR rate by adding Lenalidomide (L) to GROC (ASCO #853
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 17(9)
Background: Rituximab is associated with low incidence of hypogammaglobulinemia and little morbidity. Our experience with the combination of rituximab + chemotherapy suggested the opposite. Patients and methods: We analyzed our experience with rituxi
Autor:
Noridza Rivera-Rodriguez, Margarita Bruno, Victor Carlo, Fernando Cabanillas, Orestes Antonio Pavia, Lesley Lawrenson, Miguel M. Echenique, Viviana Negron, Idalia Liboy
Publikováno v:
Journal of Clinical Oncology. 31:e11610-e11610
e11610 Background: Achieving a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) has been associated with improved disease free survival (DFS) and overall survival (OS). The Residual Cancer Burden Score (RCB) method is a useful
Autor:
Kendra Sweet, Robert M. Crescentini, Lubomir Sokol, Jijun Liu, Julio C. Chavez, Jennifer L. Cultrera, Celeste M. Bello, Samir Dalia, Fernando Cabanillas, Idalia Liboy, Eduardo M. Sotomayor
Publikováno v:
Journal of Clinical Oncology. 30:8084-8084
8084 Background: Relapsed/refractory non-Hodgkin lymphomas (NHL) have no standard of care. A variety of salvage chemotherapy options are available. We previously reported results of our phase II trial using gemcitabine, rituximab and oxaliplatin (GRO
Autor:
Eduardo M. Sotomayor, Idalia Liboy, Lubomir Sokol, Jijun Liu, Fernando Cabanillas, Jennifer L. Cultrera, Celeste M. Bello, Enrique Santana
Publikováno v:
Blood. 116:2879-2879
Abstract 2879 Background: Non-Hodgkin's Lymphomas (NHL) are heterogeneous group hematologic malignancies. Although diffuse large B-cell lymphoma can be treated effectively with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednis
Autor:
Maribel Cotto, Fernando Cabanillas, Ezequiel Rivera, Orestes Antonio Pavia, Idalia Liboy, Margarita Bruno
Publikováno v:
Blood. 116:2789-2789
Abstract 2789 Background: Standard front line therapy for large B cell lymphoma is R-CHOP every 21 days. However, a randomized study by Pfreundschuh comparing CHOP every 21 vs. CHOP every 14 days showed an advantage in favor of CHOP-14 (Pfreundschuh
Autor:
Viviana Freire, Jorge W. Perdomo, Orestes Antonio Pavia, Ezequiel Rivera, Jorge R. Toro, Idalia Liboy, Norman Maldonado, Clara Salgado, Fernando Cabanillas
Publikováno v:
Blood. 112:3588-3588
The FDG-PET/CT scan has become a standard tool in management of NHL. Failure to achieve an early metabolic CR (mCR) has been previously associated with a poor outcome and is considered as an adverse prognostic feature. Most studies which have support